$1.6B awarded to Novavax for COVID-19 vaccine

By The Science Advisory Board staff writers

July 9, 2020 -- Novavax was awarded $1.6 billion by the U.S. government through Operation Warp Speed to deliver 100 million doses of a COVID-19 vaccine as early as late 2020.

The vaccine candidate, NVX-CoV2373, consists of a stable, prefusion protein manufactured using Novavax's proprietary nanoparticle technology and Matrix-M adjuvant.

Under the agreement, Novavax will rapidly ramp up large-scale manufacturing and transition into ongoing production, including storage and distribution of large quantities of the vaccine as needed. The funding will support late-stage clinical studies to determine the safety and efficacy of the vaccine candidate, including a phase III clinical trial with up to 30,000 participants beginning in the fall of 2020. Funds will also support the company's plans to file for licensure with the U.S. Food and Drug Administration.

The agreement also includes a follow-on agreement for additional production and procurement support to meet Operation Warp Speed's vaccine production goal.

Preliminary results for phase I/II clinical trials are expected at the end of July and immunity, safety, and efficacy studies are expected to begin shortly. These trials are supported with $388 million from the Coalition for Epidemic Preparedness Innovations. The Department of Defense is also investing $60 million to advance clinical development of NVX-CoV2373.

AGC to manufacture adjuvant for Novavax COVID-19 vaccine
AGC Biologics announced it is partnering with Novavax for large-scale good manufacturing practices production of critical components for Novavax's coronavirus...
NIH leadership discusses COVID-19 vaccine collaborations
Public-private partnerships could help meet the unprecedented need to manufacture and distribute safe and effective COVID-19 vaccines around the globe,...
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...

Copyright © 2020 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter